Morepen Laboratories Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.33 as of 18 May 15:30 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 16.5 on March 2021 to 26.6 on March 2025 . This represents a CAGR of 10.02% over 5 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 176.64 crore on March 2021 to ₹ 464.72 crore on March 2025 . This represents a CAGR of 21.34% over 5 years The revenue of Morepen Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 487.97 crore. This represent the decline of -100% The revenue of Sakar Healthcare Ltd for the Mar '26 is ₹ 71.27 crore as compare to the Dec '25 revenue of ₹ 70.85 crore. This represent the growth of 0.59% The ebitda of Morepen Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 50.12 crore. This represent the decline of -100% The ebitda of Sakar Healthcare Ltd for the Mar '26 is ₹ 26.41 crore as compare to the Dec '25 ebitda of ₹ 19.1 crore. This represent the growth of 38.27% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 11.02 crore over 8 quarters. This represents a CAGR of 113.84% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Morepen Laboratories Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Sakar Healthcare Ltd?

Market cap of Morepen Laboratories Ltd is 2,264 Cr while Market cap of Sakar Healthcare Ltd is 1,735 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Sakar Healthcare Ltd?

The stock performance of Morepen Laboratories Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Sakar Healthcare Ltd?

As of May 18, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.33. On the other hand, Sakar Healthcare Ltd stock price is INR ₹779.95.

How do dividend payouts of Morepen Laboratories Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.